{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T11:03:00Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 20.6, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09548-0ff1-7f70-94a5-499d717fa31e\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: loteprednol\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 044: 1001 reg", "usd": 0.0, "recall": true }, "codex": { "seconds": 58.3, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09548-1003-7993-86f1-f25a2c7b90bf\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: loteprednol\nRegistry id: vr.tr.loteprednol\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\n" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:49:25+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:32+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q72487729", "registryId": "vr.tr.loteprednol", "name": "loteprednol", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q72487729/", "model": { "registry_id": "vr.tr.loteprednol", "name": "loteprednol", "purpose": "Enable an agent to identify the substance registered as loteprednol, assess its material quality, and determine which handling or downstream uses its verified identity and evidence support.", "definition": "Loteprednol is a synthetic corticosteroid whose etabonate ester is used in ophthalmic medicines to suppress inflammation.", "scope_statement": "This model owns the chemical identity, composition, material state, quality, stability, and handling constraints of vr.tr.loteprednol, while keeping the unresolved relationship between the registry name loteprednol and loteprednol etabonate explicit.", "in_scope": [ "Exact molecular identity and stereochemistry represented by the registry name", "Relationship between loteprednol, loteprednol etabonate, and other explicitly identified derivatives or transformation products", "Bulk substance composition, purity, impurities, and solid form", "Physical properties and stability under recorded conditions", "Substance-level handling constraints and evidence supporting suitability for downstream pharmaceutical manufacture" ], "out_of_scope": [ "Finished ophthalmic products, their excipients, packaging, and delivery devices", "Patient diagnosis, prescribing, dosing, and treatment selection", "Manufacturing plant design and complete synthesis procedures", "Independent models of derivatives or metabolites not established as the registry referent", "Product-specific marketing authorizations and clinical efficacy assessments" ], "distinguishing_features": [ "Require an explicit structure comparison before treating a record labelled loteprednol etabonate as an exact match for loteprednol.", "Compare stereochemical assignments as well as molecular connectivity; a matching formula alone does not establish identity.", "Require analytical evidence that distinguishes the intended substance from closely related steroidal compounds and transformation products.", "Distinguish bulk substance purity from the active-ingredient concentration of a formulated ophthalmic product." ], "characteristics": [ { "name": "Registry name resolution", "kind": "state", "unit_or_values": "unresolved | exact structure established | conflicting identity evidence", "why_it_matters": "Prevents evidence for a similarly named derivative from being silently assigned to this entry." }, { "name": "Molecular and stereochemical identity", "kind": "category", "unit_or_values": "Verified structure with stereochemical descriptors, molecular formula, and structure identifiers", "why_it_matters": "Defines which chemical entity measurements and handling decisions concern." }, { "name": "Relationship to loteprednol etabonate", "kind": "relation", "unit_or_values": "Evidence-backed exact-name equivalence, distinct derivative relationship, or unresolved relationship", "why_it_matters": "Controls whether etabonate records can support this model without changing registry granularity." }, { "name": "Assay and reporting basis", "kind": "measurement", "unit_or_values": "% mass fraction or other validated assay unit; as-is, dried, or solvent-free basis explicitly stated", "why_it_matters": "Separates actual substance content from water, residual solvent, and related compounds." }, { "name": "Related-substance profile", "kind": "measurement", "unit_or_values": "Identity and concentration of individual impurities, with method, detection limit, and reporting basis", "why_it_matters": "An acceptable total assay can conceal a consequential impurity or transformation product." }, { "name": "Solid form and particle characteristics", "kind": "category", "unit_or_values": "Observed crystalline or amorphous form, hydrate or solvate status, and particle-size distribution when relevant", "why_it_matters": "Supports comparison of lots and evaluation of suitability for a specified formulation process." }, { "name": "Condition-dependent physical properties", "kind": "measurement", "unit_or_values": "Solubility in mg/mL; thermal transitions in °C; solvent, pH, temperature, and method recorded as applicable", "why_it_matters": "Property values are transferable only when both chemical identity and measurement conditions match." }, { "name": "Storage and handling status", "kind": "state", "unit_or_values": "Within documented conditions | excursion under assessment | restricted | unknown", "why_it_matters": "Links actual lot history to stability evidence and permitted handling." } ], "affordances": [ "Resolve a supplier or reference record against the registry entry using structure-level evidence.", "Compare lot certificates and analytical results on a consistent assay basis.", "Flag derivative, stereochemical, or formulation mismatches before reusing evidence.", "Assess whether a lot satisfies a documented downstream material specification.", "Identify storage excursions requiring testing or review.", "Retrieve identity-specific handling requirements while marking unsupported limits as unknown." ], "agent_conduct": { "may": [ "Explain what loteprednol is and what it is used for in general terms.", "Read medicine labels and report strength, form and expiry." ], "must_not": [ "Recommend, start or stop eye steroid treatment for a person without a prescriber.", "Present it as safe for long unsupervised use.", "Supply prescription eye drops to someone without a valid prescription." ], "requires_human": [ "Any decision to start or change steroid eye treatment.", "Advising a person whose eye pressure or infection status is unknown." ] }, "ethics": { "considerations": [ "Steroid eye drops can harm sight if used without monitoring.", "Patients need clear, honest information about side effects." ], "affected_parties": [ "Patients with eye inflammation", "Prescribers and pharmacists" ] }, "owners": { "steward": "The prescriber and the patient; medicines regulators authorize the products.", "master_systems": [ "National medicines authorization registers" ] }, "visual_identification": [ "Usually seen as a labelled eye drop or gel bottle with a prescription label." ], "failure_modes_and_hazards": [ "Long use can raise eye pressure and contribute to cataract.", "Steroids can worsen some eye infections." ], "what_it_is_for": [ "Loteprednol is encountered in chemical identification, corticosteroid research and records concerning related pharmaceutical substances.", "Its etabonate ester is used in ophthalmic medicines for inflammation, so substance records must distinguish loteprednol from loteprednol etabonate." ], "standards_and_regulation": [ "The Globally Harmonized System of Classification and Labelling of Chemicals, issued by the United Nations, provides the framework for assessing chemical hazards and communicating applicable classifications where implemented." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q72487729: loteprednol", "url": "https://www.wikidata.org/wiki/Q72487729", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Loteprednol", "url": "https://en.wikipedia.org/wiki/Loteprednol", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "loteprednol-identity-boundary", "name": "Loteprednol identity boundary", "description": "Establish what chemical entity the registry name denotes and which adjacent names refer to something different.", "rationale": "The unresolved loteprednol versus loteprednol etabonate boundary can invalidate every later property or use assertion.", "layers": [ { "id": "name-to-structure-resolution", "name": "Name-to-structure resolution", "description": "Connect the registry label to an evidenced molecular structure.", "findings": [ { "id": "exact-registry-referent", "name": "Exact registry referent", "description": "Record the supported referent without assuming that a shortened medicinal name denotes a separate or identical chemical substance.", "questions": [ { "text": "What original registry source establishes the molecular structure intended by loteprednol?", "kind": "provenance", "id": "exact-registry-referent-q01" }, { "text": "Does that source use loteprednol as an exact chemical name, a shortened name for loteprednol etabonate, or an unresolved label?", "kind": "definition", "id": "exact-registry-referent-q02" } ] } ] }, { "id": "stereochemistry-and-adjacent-entities", "name": "Stereochemistry and adjacent entities", "description": "Separate exact identity from derivative relationships and structural similarity.", "findings": [ { "id": "structure-equivalence-test", "name": "Structure equivalence test", "description": "Require connectivity and stereochemical agreement before merging identifiers or evidence.", "questions": [ { "text": "Which connectivity and stereochemical descriptors must match for a candidate loteprednol record to represent this entry?", "kind": "definition", "id": "structure-equivalence-test-q01" }, { "text": "Which records for loteprednol etabonate or transformation products represent related entities rather than exact identity matches?", "kind": "boundary", "id": "structure-equivalence-test-q02" } ] } ] } ] }, { "id": "loteprednol-material-quality", "name": "Loteprednol material quality", "description": "Describe the actual content and analytical identity of a lot labelled loteprednol.", "rationale": "A supplier label or nominal assay does not establish that the lot contains the resolved chemical entity at suitable quality.", "layers": [ { "id": "identity-and-assay-evidence", "name": "Identity and assay evidence", "description": "Tie identification and content measurements to an appropriate reference material and reporting basis.", "findings": [ { "id": "reference-matched-assay", "name": "Reference-matched assay", "description": "Record whether the analytical reference and method address the exact entity represented by this entry.", "questions": [ { "text": "Does the reference standard certify the resolved loteprednol structure or a different entity such as loteprednol etabonate?", "kind": "provenance", "id": "reference-matched-assay-q01" }, { "text": "What is the measured assay, its uncertainty, and its water or solvent correction basis?", "kind": "measurement", "id": "reference-matched-assay-q02" } ] } ] }, { "id": "related-compounds-and-residues", "name": "Related compounds and residues", "description": "Characterize impurities that could obscure identity or limit a proposed material use.", "findings": [ { "id": "discriminating-impurity-profile", "name": "Discriminating impurity profile", "description": "Track evidenced related compounds, stereochemical impurities, and process residues without presuming their identities.", "questions": [ { "text": "Which method distinguishes the intended loteprednol entity from relevant derivatives, stereoisomers, and observed degradation products?", "kind": "measurement", "id": "discriminating-impurity-profile-q01" }, { "text": "Which individual impurity and residual-solvent limits apply to the proposed material grade, and what document establishes them?", "kind": "provenance", "id": "discriminating-impurity-profile-q02" } ] } ] } ] }, { "id": "loteprednol-physical-state-and-stability", "name": "Loteprednol physical state and stability", "description": "Connect observed physical form and environmental exposure to identity-specific material behavior.", "rationale": "Measurements for another derivative or a formulated suspension cannot establish the behavior of the bulk registry substance.", "layers": [ { "id": "solid-form-and-solubility", "name": "Solid form and solubility", "description": "Describe the tested form and the conditions under which physical properties were measured.", "findings": [ { "id": "form-specific-property-record", "name": "Form-specific property record", "description": "Keep solid-form, thermal, particle, and solubility observations attached to the exact tested material.", "questions": [ { "text": "What solid form, hydrate or solvate status, and particle-size distribution were established for the tested loteprednol sample?", "kind": "measurement", "id": "form-specific-property-record-q01" }, { "text": "Which solubility and thermal measurements concern this exact entity, and under what solvent, pH, temperature, and test conditions?", "kind": "measurement", "id": "form-specific-property-record-q02" } ] } ] }, { "id": "transformation-and-storage-history", "name": "Transformation and storage history", "description": "Relate changes during storage to analytical evidence and qualified storage conditions.", "findings": [ { "id": "identity-specific-stability", "name": "Identity-specific stability", "description": "Establish observed degradation behavior without transferring stability claims from etabonate products or other formulations.", "questions": [ { "text": "What studies establish changes in assay or impurity profile under light, moisture, heat, or relevant solution conditions for the resolved entity?", "kind": "provenance", "id": "identity-specific-stability-q01" }, { "text": "Following a recorded storage excursion, what evidence is required to release, retest, or restrict the lot?", "kind": "action", "id": "identity-specific-stability-q02" } ] } ] } ] }, { "id": "loteprednol-handling-and-use-eligibility", "name": "Loteprednol handling and use eligibility", "description": "Determine what handling and material-use decisions are supported for the identified substance and lot.", "rationale": "Pharmaceutical naming and association with a medicine do not establish a bulk lot's safety classification, grade, or eligibility for use.", "layers": [ { "id": "substance-hazard-evidence", "name": "Substance hazard evidence", "description": "Locate handling evidence that matches the resolved chemical identity and physical form.", "findings": [ { "id": "identity-matched-handling-controls", "name": "Identity-matched handling controls", "description": "Record applicable hazard classifications and exposure controls, including gaps in identity-specific evidence.", "questions": [ { "text": "Which safety data sheet and jurisdictional hazard records explicitly match the resolved loteprednol entity and supplied form?", "kind": "provenance", "id": "identity-matched-handling-controls-q01" }, { "text": "What documented controls govern weighing, dust containment, accidental release, and disposal, and are any exposure limits actually established?", "kind": "action", "id": "identity-matched-handling-controls-q02" } ] } ] }, { "id": "grade-and-pharmaceutical-boundary", "name": "Grade and pharmaceutical boundary", "description": "Separate substance-level suitability from the authorization and clinical use of finished products.", "findings": [ { "id": "supported-downstream-use", "name": "Supported downstream use", "description": "Make proposed use conditional on exact identity, documented grade, and the receiving process specification.", "questions": [ { "text": "What evidence establishes this lot's grade and suitability for the proposed research or pharmaceutical manufacturing use?", "kind": "action", "id": "supported-downstream-use-q01" }, { "text": "Which claims concern a finished loteprednol etabonate product and therefore require a linked product model rather than a substance-level conclusion?", "kind": "boundary", "id": "supported-downstream-use-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "First verify whether the registry intends loteprednol itself or uses the name as shorthand for loteprednol etabonate.", "Uses and hazards listed here concern ophthalmic administration of the etabonate ester, not established clinical use of unesterified loteprednol.", "CAS, PubChem and EC identifiers, physical constants and substance-specific hazard classifications are omitted because they cannot be recalled confidently; no sources were consulted." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of loteprednol this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "loteprednol", "note": "Distinguish the named substance from loteprednol etabonate when assigning chemical identifiers." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of loteprednol this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "As loteprednol etabonate, treatment of steroid-responsive ocular inflammation.", "As loteprednol etabonate, control of inflammation following ocular surgery.", "As loteprednol etabonate, treatment of seasonal allergic conjunctivitis in certain ophthalmic products." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of loteprednol this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Ophthalmic corticosteroid use can elevate intraocular pressure and contribute to glaucoma.", "Prolonged ophthalmic corticosteroid use can contribute to posterior subcapsular cataract formation.", "Suppression of local immune responses can mask or worsen ocular infections.", "Ophthalmic corticosteroids can delay healing and increase perforation risk in eyes with corneal or scleral thinning." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of loteprednol this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Approved indications, available formulations and prescribing restrictions for loteprednol etabonate products vary by jurisdiction." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of loteprednol this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "loteprednol etabonate", "difference": "The etabonate ester is a distinct chemical entity and the active ingredient commonly used in ophthalmic products; its identifiers and physical properties should not automatically be assigned to loteprednol." }, { "name": "prednisolone", "difference": "A chemically distinct corticosteroid with different substituents and metabolism; it is not a synonym for loteprednol." }, { "name": "loteprednol etabonate ophthalmic suspension", "difference": "A formulated medicinal product containing the ester, excipients and a specified concentration, rather than the isolated substance." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of loteprednol this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Does vr.tr.loteprednol denote a distinct molecular entity or use loteprednol as a shortened name for loteprednol etabonate?", "Which authoritative structure, stereochemical specification, CAS number, PubChem CID, and any applicable EC identifier match the resolved referent?", "Which identity-specific physical-property and stability measurements are available, rather than measurements of etabonate or finished ophthalmic formulations?", "Which analytical standards, impurity limits, and material grades are established for the exact entity?", "Which jurisdiction-specific hazard classifications and exposure limits exist for the resolved substance, and where does evidence remain absent?" ], "statistics": { "bundles": 5, "layers": 9, "findings": 14, "questions": 22 } }